EA201792418A1 - Применение cd24 для снижения уровней холестерина липопротеинов низкой плотности - Google Patents

Применение cd24 для снижения уровней холестерина липопротеинов низкой плотности

Info

Publication number
EA201792418A1
EA201792418A1 EA201792418A EA201792418A EA201792418A1 EA 201792418 A1 EA201792418 A1 EA 201792418A1 EA 201792418 A EA201792418 A EA 201792418A EA 201792418 A EA201792418 A EA 201792418A EA 201792418 A1 EA201792418 A1 EA 201792418A1
Authority
EA
Eurasian Patent Office
Prior art keywords
application
low density
reduce low
lipoprotein levels
density cholesterol
Prior art date
Application number
EA201792418A
Other languages
English (en)
Other versions
EA038520B1 (ru
Inventor
Ян Лю
Пань Чжэн
Original Assignee
Онкоиммьюн, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Онкоиммьюн, Инк. filed Critical Онкоиммьюн, Инк.
Publication of EA201792418A1 publication Critical patent/EA201792418A1/ru
Publication of EA038520B1 publication Critical patent/EA038520B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/32—Cardiovascular disorders
    • G01N2800/323—Arteriosclerosis, Stenosis

Abstract

Настоящее изобретение относится к применению белка CD24 для снижения уровней холестерина липопротеинов низкой плотности, лечения и предупреждения атеросклероза и для снижения риска сердечно-сосудистого заболевания.
EA201792418A 2015-05-07 2016-05-06 Применение гуманизированного слитого белка cd24 для снижения уровней холестерина липопротеинов низкой плотности EA038520B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562158157P 2015-05-07 2015-05-07
PCT/US2016/031109 WO2016179456A1 (en) 2015-05-07 2016-05-06 Use of cd24 for lowering low-density lipoprotein cholesterol levels

Publications (2)

Publication Number Publication Date
EA201792418A1 true EA201792418A1 (ru) 2018-02-28
EA038520B1 EA038520B1 (ru) 2021-09-09

Family

ID=57218627

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201792418A EA038520B1 (ru) 2015-05-07 2016-05-06 Применение гуманизированного слитого белка cd24 для снижения уровней холестерина липопротеинов низкой плотности

Country Status (18)

Country Link
US (2) US10369197B2 (ru)
EP (1) EP3292144B1 (ru)
JP (1) JP6751756B2 (ru)
KR (1) KR20170141216A (ru)
CN (1) CN107531772B (ru)
AU (1) AU2016258084B2 (ru)
BR (1) BR112017022394A2 (ru)
CA (1) CA2982612A1 (ru)
EA (1) EA038520B1 (ru)
ES (1) ES2829235T3 (ru)
HK (1) HK1249521A1 (ru)
HR (1) HRP20201651T1 (ru)
HU (1) HUE051866T2 (ru)
IL (1) IL255086B (ru)
MX (1) MX2017014095A (ru)
PT (1) PT3292144T (ru)
WO (1) WO2016179456A1 (ru)
ZA (1) ZA201706846B (ru)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA038520B1 (ru) * 2015-05-07 2021-09-09 Онкоиммьюн, Инк. Применение гуманизированного слитого белка cd24 для снижения уровней холестерина липопротеинов низкой плотности
JP2020510020A (ja) 2017-03-07 2020-04-02 オンコイミューン， インコーポレイテッド 全身性エリテマトーデスを治療するために可溶性ｃｄ２４を使用する方法
WO2019113123A1 (en) * 2017-12-04 2019-06-13 Precithera, Inc. TGF-ß RECEPTOR FUSION PROTEINS AND OTHER TGF-ß ANTAGONISTS FOR REDUCING TGF-ß SIGNALING
WO2019173310A1 (en) * 2018-03-05 2019-09-12 Oncoimmune, Inc. Methods of use of soluble cd24 for treating acquired immune deficiency syndrome (hiv/aids)
SG11202011964SA (en) * 2018-06-04 2020-12-30 Oncoimmune Inc Methods of use of cd24 for the prevention and treatment of leukemia relapse
AU2020219785A1 (en) * 2019-02-06 2021-09-02 Children's Research Institute, Children's National Medical Center Targeting CD24-Siglec interactions for treating subjects with prediabetes or diabetes
AU2020219216A1 (en) * 2019-02-06 2021-09-02 Oncoimmune, Inc. Targeting CD24-Siglec interactions for the treatment and prevention of nonalcoholic steatohepatitis

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6544566B1 (en) * 1999-04-23 2003-04-08 Protein Technologies International, Inc. Composition containing plant sterol, soy protein and isoflavone for reducing LDL cholesterol
WO2001072325A1 (en) * 2000-03-29 2001-10-04 The Ohio State University Research Foundation Methods of blocking tissue destruction by autoreactive t cells
CN1323544A (zh) * 2000-05-13 2001-11-28 蛋白质技术国际公司 降低低密度脂蛋白胆固醇浓度的组合物和方法
EP2231184A4 (en) * 2007-12-21 2012-02-15 Univ Rochester CD24 AS A STEM CELL MARKER FOR BRAIN TUMOR AND DIAGNOSTIC AND THERAPEUTIC TARGET MOLECULAR IN PRIMARY NEURONAL AND GLIAL BRAIN TUMORS
US8163281B2 (en) * 2009-03-04 2012-04-24 The Regents Of The University Of Michigan Treatment of drug-related side effect and tissue damage by targeting the CD24-HMGB1-Siglec10 axis
US8354520B2 (en) * 2009-12-10 2013-01-15 Kaohsiung Medical University Composition and method for treating atherosclerosis, method for determining if a subject has atherosclerosis and method of screening an anti-atherosclerotic drug
WO2011139820A1 (en) * 2010-04-28 2011-11-10 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
US20130231464A1 (en) * 2010-04-28 2013-09-05 Oncolmmune, Inc. Methods of use of soluble cd24 for therapy of rheumatoid arthritis
CN104039134A (zh) * 2011-06-10 2014-09-10 宾夕法尼亚大学董事会 细胞组学血管健康概况分析的系统和方法
EA038520B1 (ru) * 2015-05-07 2021-09-09 Онкоиммьюн, Инк. Применение гуманизированного слитого белка cd24 для снижения уровней холестерина липопротеинов низкой плотности

Also Published As

Publication number Publication date
EA038520B1 (ru) 2021-09-09
US10369197B2 (en) 2019-08-06
JP6751756B2 (ja) 2020-09-09
HUE051866T2 (hu) 2021-03-29
US20190307841A1 (en) 2019-10-10
KR20170141216A (ko) 2017-12-22
MX2017014095A (es) 2018-03-16
EP3292144A1 (en) 2018-03-14
PT3292144T (pt) 2020-11-05
CN107531772B (zh) 2021-09-21
BR112017022394A2 (pt) 2018-07-17
ES2829235T3 (es) 2021-05-31
IL255086A0 (en) 2017-12-31
CN107531772A (zh) 2018-01-02
AU2016258084B2 (en) 2020-01-30
AU2016258084A1 (en) 2017-11-02
US20180110828A1 (en) 2018-04-26
CA2982612A1 (en) 2016-11-10
HK1249521A1 (zh) 2018-11-02
EP3292144B1 (en) 2020-08-26
EP3292144A4 (en) 2018-11-14
IL255086B (en) 2021-08-31
JP2018515605A (ja) 2018-06-14
WO2016179456A1 (en) 2016-11-10
ZA201706846B (en) 2018-12-19
US11026995B2 (en) 2021-06-08
HRP20201651T1 (hr) 2020-12-25

Similar Documents

Publication Publication Date Title
EA201792418A1 (ru) Применение cd24 для снижения уровней холестерина липопротеинов низкой плотности
EA201791460A1 (ru) N4-гидроксицитидин и связанные с ним производные и варианты противовирусного применения
EA201890754A1 (ru) Соединения и способы их применения
EA201790984A1 (ru) Анти-cd79b антитела и способы их применения
EA201590997A1 (ru) Соединения и способы их применения
EA201890453A1 (ru) Анти-angptl8 антитела и их применение
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201790998A1 (ru) Иммуннорегуляторные агенты
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
BR112017006664A2 (pt) terapias de combinação
EA201691610A1 (ru) Анти-jagged1 антитела и способы применения
BR112016018408A2 (pt) moléculas de anticorpo à lag-3 e usos das mesmas
EA201790413A1 (ru) Антитела против tigit
EA201690456A1 (ru) Способы лечения и предотвращения эндотелиальной дисфункции с применением бардоксолона метила или его аналогов
EA201691470A1 (ru) Белки, связывающие калликреин плазмы, и их применение для лечения наследственного ангионевротического отека
EA201790273A1 (ru) Флагеллиновые композиции и их применение
EA201691114A1 (ru) Биарильные соединения, применяемые при лечении заболеваний человека в онкологии, нефрологии и иммунологии
EA201692539A1 (ru) Антитела и антигенсвязывающие фрагменты, которые специфично связываются с белком тау, ассоциированным с микротрубочками
EA201890810A1 (ru) Соединения, эффективные для лечения гепатотоксичности и стеатоза печени, и их применение
EA201790922A1 (ru) Ингибиторы бромодомена
EA201691541A1 (ru) Новые анти-baff антитела
EA201592203A1 (ru) Способы лечения таупатии
EA201690064A1 (ru) Антитела к лектин-подобному рецептору 1 окисленных ldl и способы применения
NZ715582A (en) Lectin-like oxidized ldl receptor 1 antibodies and methods of use
EA201892203A1 (ru) Оксабороловые сложные эфиры, их применение